Lakeway, NY -- (SBWIRE) -- 03/07/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
Cliffs Natural Resources Inc (NYSE:CLF) stock gained 3.59% to $24.55. CLF’s stock had its target price cut by Citigroup to $32.00 in a research note issued to investors on Feb. 19.
Additionally, the company released its earnings data on February 12. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.07. The company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion.
Get Latest News, Updates on CLF Here
W.R. Grace & Co. (NYSE:GRA) shares jumped 3.57% and closed at $76.02 in the last trading session. The company, last month, announced a fourth-quarter net loss of $111.6 million, or $1.48 per share. Net income for the prior-year quarter was $58.1 million, or $0.77 per share. Adjusted profit per share was $1.11 compared to $0.89 prior-year. Fourth-quarter sales were $797.8 million declined 3.4 percent from with the prior-year quarter. Analysts expected the company to report profit of $1.06 per share on revenue of $790.13 million for the quarter.
Is GRA a Strong Buying Opportunity After The Recent Gain? Find out Here
Tempur-Pedic International Inc. (NYSE:TPX) shares decreased 0.28% to $42.88. The company, on Feb. 25, announced an update to investors on the anticipated timing for the closing of the proposed acquisition of Sealy Corporation. Sealy's Information Statement has been cleared by the Securities and Exchange Commission and was mailed to stockholders on February 22. Under the terms of the Merger Agreement with Sealy, this mailing must occur at least 20 calendar days prior to the closing of the acquisition. This condition will be satisfied on March 14, 2013.
Is TPX Signaling a Buy After The Sudden Gain? Don’t Miss Out Free Trend Analysis Here
Star Scientific, Inc.(NASDAQ:STSI) shares gained 3.54% to $2.05. STSI’s stock was downgraded by Zacks analyst from an outperform rating to a neutral rating in a research note issued to investorson Jan. 31. The current target price on the stock is $2.60.
Additionally last month, the Company announces publication of the first peer-reviewed article examining the effects of anatabine in a mouse model of the debilitating autoimmune and neurodegenerative disease multiple sclerosis (MS).
Is STSI a Strong Buying Opportunity After The Recent Slump? Find out Here
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)